Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.32
KBIO's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 4.32 )
KBIO' s 10-Year Cash to Debt Range
Min: 2.07   Max: No Debt
Current: 4.32

F-Score: 2
Z-Score: -2.32
M-Score: -4.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -92975.00
KBIO's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: -92975.00 )
KBIO' s 10-Year Operating margin (%) Range
Min: -92975   Max: -11.19
Current: -92975

-92975
-11.19
Net-margin (%) -95336.36
KBIO's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: -95336.36 )
KBIO' s 10-Year Net-margin (%) Range
Min: -95336.36   Max: -11.02
Current: -95336.36

-95336.36
-11.02
ROE (%) -69.29
KBIO's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: -69.29 )
KBIO' s 10-Year ROE (%) Range
Min: -69.29   Max: -69.29
Current: -69.29

ROA (%) -53.30
KBIO's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: -53.30 )
KBIO' s 10-Year ROA (%) Range
Min: -95.8   Max: -11.54
Current: -53.3

-95.8
-11.54
ROC (Joel Greenblatt) (%) -14822.10
KBIO's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: -14822.10 )
KBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14822.1   Max: -530.91
Current: -14822.1

-14822.1
-530.91
» KBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

KBIO Guru Trades in Q3 2013

Jean-Marie Eveillard 875,000 sh (New)
Paul Tudor Jones 125,000 sh (New)
PRIMECAP Management 4,706,675 sh (+27.84%)
» More
Q4 2013

KBIO Guru Trades in Q4 2013

Jim Simons 18,531 sh (New)
Jean-Marie Eveillard 875,000 sh (unchged)
Paul Tudor Jones Sold Out
PRIMECAP Management 4,699,975 sh (-0.14%)
» More
Q1 2014

KBIO Guru Trades in Q1 2014

Jean-Marie Eveillard 1,746,591 sh (+99.61%)
Jim Simons 29,238 sh (+57.78%)
PRIMECAP Management 4,691,475 sh (-0.18%)
» More
Q2 2014

KBIO Guru Trades in Q2 2014

Jim Simons 245,301 sh (+738.98%)
Jean-Marie Eveillard 1,746,591 sh (unchged)
PRIMECAP Management 4,475,700 sh (-4.6%)
» More
» Details

Insider Trades

Latest Guru Trades with KBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Add 99.61%0.01%$2.61 - $5.42 $ 1.59-57%1746591
Jean-Marie Eveillard 2013-09-30 New Buy0.01%$4.45 - $6.46 $ 1.59-72%875000
PRIMECAP Management 2013-09-30 Add 27.84%0.01%$4.45 - $6.46 $ 1.59-72%4706675
PRIMECAP Management 2013-03-31 New Buy0.03%$6 - $8 $ 1.59-77%3681675
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.30
KBIO's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 1.30 )
KBIO' s 10-Year P/B Range
Min: 1   Max: 3.5
Current: 1.3

1
3.5
P/S 3333.30
KBIO's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 3333.30 )
KBIO' s 10-Year P/S Range
Min: 0   Max: 3508.7
Current: 3333.3

0
3508.7
EV-to-EBIT 0.09
KBIO's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 0.09 )
KBIO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.09

Current Ratio 5.21
KBIO's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 5.21 )
KBIO' s 10-Year Current Ratio Range
Min: 2.29   Max: 11.14
Current: 5.21

2.29
11.14
Quick Ratio 5.21
KBIO's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 5.21 )
KBIO' s 10-Year Quick Ratio Range
Min: 2.29   Max: 11.14
Current: 5.21

2.29
11.14

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.40
KBIO's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 1.40 )
KBIO' s 10-Year Price/Net Cash Range
Min: 1.91   Max: 3.1
Current: 1.4

1.91
3.1
Price/Net Current Asset Value 1.40
KBIO's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 1.40 )
KBIO' s 10-Year Price/Net Current Asset Value Range
Min: 1.91   Max: 3.1
Current: 1.4

1.91
3.1
Price/Tangible Book 1.30
KBIO's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 1.30 )
KBIO' s 10-Year Price/Tangible Book Range
Min: 1.76   Max: 2.86
Current: 1.3

1.76
2.86
Earnings Yield (Greenblatt) 1062.00
KBIO's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KBIO: 1062.00 )
KBIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 3440.9
Current: 1062

0
3440.9

Business Description

Industry: »
Compare: » details
Traded in other countries:0KB.Germany
KaloBios Pharmaceuticals Inc is a biopharmaceutical company focused on the development of monoclonal antibody therapeutics for diseases that represent a significant burden to society and to patients and their families.
» More Articles for KBIO

Headlines

Articles On GuruFocus.com
No related article found.


More From Other Websites
KALOBIOS PHARMACEUTICALS INC Financials Aug 19 2014
Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer... Aug 14 2014
KaloBios (KBIO) Enters Oversold Territory Aug 13 2014
Relypsa (RLYP) Worth Watching: Stock Gains 13.3% Aug 11 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results Aug 07 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 07 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 28 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 20 2014
Will KaloBios (KBIO) Continue to Surge Higher? Jun 13 2014
KaloBios to Present at 9th Annual JMP Securities Healthcare Conference Jun 11 2014
KaloBios (KBIO) Worth Watching: Stock Jumps 12.7% Jun 11 2014
KaloBios Pharmaceuticals (KBIO) Worth Watching: Stock Up 5.3% May 29 2014
KaloBios to Present at Jefferies 2014 Global Healthcare and BBC Boston CEO Conferences May 21 2014
KaloBios (KBIO) is now in Oversold Territory May 12 2014
KaloBios reports Q1 EPS (32c), consensus (38c) May 08 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 08 2014
KaloBios Provides First Quarter 2014 Financial Results May 08 2014
Ted W. Love, M.D., Named Chairman of the Board of KaloBios May 06 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers May 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide